Aim Faecal Calprotectin is recommended as a noninvasive indicative marker of the extent of intestinal mucosal inflammation associated with inflammatory bowel disease and cow’s milk allergy(CMA).We aim to demonstrate the usability of measuring faecal Calprotectin as a simple, noninvasive and reliable test in following up disease activity and pointing out relapses in patients with gastrointestinal symptoms associated with colorectal inflammation.

Methods Newly diagnosed 32patients were recruited into the CMA group while 19healthy symptomless subjects were included into the control group.

Results Patients in the CMA group were shown to exhibit higher faecal Calprotectin levels than their controls. The levels were significantly lower in the CMA patients after diet modification than they were before diet modification. Patients in I˙gE mediated group fecal calprotectin level were found higher than control group, but there were no significant difference istatistically. Patients in non-I˙gE mediated group had istatistically higher fecal calprotectin levels than controls. Patients in non-I˙gE mediated group had higher level of faecal calprotectin than patients in I˙gE mediated group. After exclution diet, we observed significant regression of fecal calprotectin in both groups.

Conclusion It has been shown that the Calprotectin levels that were initially high had regressed after exclution diet. Thus it is suggested that faecal Calprotectin can help to show fecal inflammation due to CMP, response to exclution diet and followup of the disease activity in CMA. Especially patients in nonI˙gE mediated group that shows more intestinal signs had higher fecal calprotectin than I˙gE mediated group that shows less intestinal signs. Thus we can say that non I˙gE mediated group has high intestinal inflammation than non I˙gE mediated group.